01 Industry overview
The oncology industry at a glance
The global oncology drugs market is estimated at $280.7 billion in 2026, with demand supported by rising cancer incidence, expanding targeted therapies and rapid regulatory activity.
- $280.7B[3]
- Market size, 2026
- 9.8%[3]
- Forecast CAGR, 2026–2033
- 41.2%[3]
- North America share, 2025
- 2,041,910[25]
- U.S. new cases, 2025
- Market size
- The global oncology drugs market is estimated at $257.6 billion in 2025 and $280.7 billion in 2026. The market includes chemotherapy, targeted therapy, immunotherapy and other cancer medicines.[3]
- Forecast & CAGR
- The global oncology drugs market is projected to reach $541.6 billion by 2033, representing a 9.8% CAGR from 2026 to 2033. Cell and gene therapy is forecast to be the fastest-growing drug-class segment, at a 17.5% CAGR.[3]
- Market share & regions
- North America held 41.2% of global oncology-drug-market revenue in 2025, making it the leading regional market. The region’s position is associated with advanced oncology infrastructure and high adoption of innovative therapies.[3]
- Segmentation
- Chemotherapy accounted for 31.5% of oncology-drug revenue in 2025. The market is also segmented by targeted therapy, immunotherapy, cancer type, route of administration, drug type, distribution channel and region.[3]
- Key players & concentration
- The oncology market is led by large pharmaceutical companies with broad portfolios spanning immunotherapy, targeted medicines and antibody–drug conjugates. Public market-share concentration data for the leading companies was not reliably disclosed in the sources reviewed.[3]
- Trends, drivers & challenges
- Global cancer incidence reached 19,976,499 new cases and 9,743,832 deaths in 2022. The World Health Organization projects more than 35 million new cases annually by 2050, a 77% increase from 2022, while the industry faces challenges from treatment affordability, unequal access and clinical-development complexity.[26][27]
- Consumer behavior & competition
- In the United States, breast cancer was projected to be the most common cancer in 2025, with 319,750 new cases, followed by prostate cancer at 313,780 and lung and bronchus cancer at 226,650. Competition is increasingly centered on biomarker-defined indications, combination regimens and differentiated delivery technologies.[25][28]
- M&A
- Oncology represented 20% of biopharma M&A value in 2025 among transactions tracked by IQVIA. Notable 2025 cancer-focused transactions included Eli Lilly’s $2.5 billion acquisition of Scorpion Therapeutics, Merck KGaA’s $3.4 billion acquisition of SpringWorks Therapeutics and Sanofi’s $9.5 billion acquisition of Blueprint Medicines.[29][30]
- Regulation
- The FDA reported 17 new molecular entity or original biologics-license oncology approvals in 2025, comprising 9 regular and 8 accelerated approvals. It also reported 15 other original non-NME NDA or BLA approvals and 38 supplemental approvals for new indications.[28]
- Latest news
- The FDA’s 2025 Oncology Center of Excellence report recorded 17 NME or original BLA approvals, 15 other original NDA or BLA approvals and 38 supplemental approvals for new indications. The report also recorded 1,277 oncology sponsor meetings during 2025, indicating continued development activity across the sector.[28]
02 Ranking
Top 10 Companies in the Oncology Industry
The leading companies in the oncology industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
Eli Lilly and Company stands out for oncology medicines because it launched Inluriyo for breast cancer and expanded Jaypirca in blood cancers in 2025, while Roche focuses on cancer medicines and diagnostics since oncology is identified as a primary healthcare focus across medicines and diagnostics.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in oncology medicines
Eli Lilly and Company
US
Ranked #1 · 9.8 · Oncology medicines
Why we picked it: It reported revenue growth of 44.7% and an R&D budget at 20.5% of revenue while scaling oncology launches.
Leader in cancer diagnostics
Roche
CH
Ranked #2 · 9.1 · Cancer diagnostics
Why we picked it: It pairs cancer medicines with diagnostics while reporting R&D at 19.8% of revenue and revenue growth of 7%.
#3 overall
Johnson & Johnson
US
Ranked #3 · 8.9 · Oncology medicines
Why we picked it: It links oncology growth to specific medicines and cell therapy categories while holding R&D at 15.6% of revenue.
Pick 1 is the #1 company overall. Pick 2 is the highest-ranked company in the top 5 that adds a new segment; no further segment places in the top 5, so pick 3 follows rank.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly and Company Oncology medicines · US | 9.8 | 9.5 | 9.9 | 9.9 | 9.9 | |
Company snapshot · Eli Lilly and Company · Data as of November 20, 2026 Lilly launched Inluriyo for breast cancer and expanded Jaypirca in blood cancers in 2025.[31]
| |||||||
| 2 | Roche Cancer diagnostics · CH | 9.1 | 9.8 | 8.0 | 8.8 | 9.9 | |
Company snapshot · Roche · Data as of November 20, 2026 Roche identifies oncology as a primary healthcare focus across medicines and diagnostics.[32]
| |||||||
| 3 | Johnson & Johnson Oncology medicines · US | 8.9 | 9.9 | 7.8 | 8.3 | 9.0 | |
Company snapshot · Johnson & Johnson · Data as of November 20, 2026 Oncology growth in 2025 was driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT.[1]
| |||||||
| 4 | AstraZeneca Oncology medicines · GB | 8.8 | 9.1 | 8.5 | 8.5 | 9.0 | |
Company snapshot · AstraZeneca · Data as of November 20, 2026 Oncology product sales totaled $23.7 billion in 2025.[33]
| |||||||
| 5 | Amgen Oncology medicines · US | 8.8 | 8.9 | 8.7 | 8.5 | 9.0 | |
Company snapshot · Amgen · Data as of November 20, 2026 Innovative Oncology sales grew 11% to $8.7 billion in 2025.[34]
| |||||||
| 6 | Novartis Oncology medicines and radioligand therapy, global · CH | 8.8 | 8.9 | 8.8 | 8.4 | 9.0 | |
Company snapshot · Novartis · Data as of November 20, 2026 Novartis reported major 2025 oncology sales from Kisqali, Pluvicto, Tafinlar and Jakavi.[35]
| |||||||
| 7 | Merck Oncology medicines and vaccines, global · US | 8.6 | 9.7 | 8.3 | 7.0 | 9.0 | |
Company snapshot · Merck · Data as of November 20, 2026 KEYTRUDA generated $31.7 billion in 2025 sales, making Merck a leading oncology company.[36]
| |||||||
| 8 | Astellas Oncology and targeted medicines, global · JP | 8.5 | 8.7 | 8.4 | 8.6 | 8.0 | |
Company snapshot · Astellas · Data as of November 20, 2026 Astellas lists oncology among its core marketed therapeutic areas.[37]
| |||||||
| 9 | Pfizer Oncology medicines, global · US | 8.4 | 9.6 | 8.0 | 7.3 | 8.2 | |
Company snapshot · Pfizer · Data as of November 20, 2026 Pfizer's oncology portfolio includes IBRANCE, XTANDI, PADCEV and ELREXIO.[38]
| |||||||
| 10 | Takeda Pharmaceuticals Oncology medicines, global · JP | 7.8 | 8.9 | 7.1 | 7.3 | 7.0 | |
Company snapshot · Takeda Pharmaceuticals · Data as of November 20, 2026 Takeda's oncology portfolio includes FRUZAQLA, ADCETRIS and ICLUSIG.[39]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Thomas Lindqvist. (2026, February 13). Top 10 companies in the oncology industry. In Oncology Industry Statistics. Gitnux. https://gitnux.org/oncology-industry-statistics/#top-companies
Revenue of the largest oncology companies
Johnson & Johnson leads with $94.2B in annual revenue (group level, converted to USD).
03 Statistics
Technology & AI
U.S. oncology practices show measurable AI take-up: 49% report using AI tools in 2026, and 19% use AI-powered predictive models.
AI and automation in the oncology industry
- 19% of surveyed U.S. community oncologists reported using AI-powered predictive models in 2026; the survey covered more than 200 community oncologists and practice administrators.[1]
- 49% of surveyed U.S. community oncologists reported currently using AI tools in oncology practice in 2026; the survey covered more than 200 community oncologists and practice administrators.[1]
- 55% of respondents at 102 U.S. cancer centers said in 2025 that they were experimenting unofficially with AI tools to support parts of their oncology roles; the survey received 168 responses.[2]
04 Statistics
Market Intelligence
Service-market figures frame demand alongside drugs: the global community oncology-services market reached $54.25B in 2025 and is projected to $79.95B by 2030.
Market size and service revenue in the oncology industry
- $261.1 billion was the global cancer hospital-services market in 2024, covering cancer as an inpatient-services segment within hospital services.[3]
- $54.25 billion was the global community oncology-services market in 2025, covering small, medium and large community oncology clinics across medical, radiation and surgical oncology.[4]
- $200 billion was the estimated U.S. cancer-care market in 2024, covering oncology spending across providers, payers and related cancer-care services.[5]
Growth forecasts for the oncology industry
- The global cancer hospital-services market is projected to reach $311.9 billion by 2030 from $261.1 billion in 2024, a 3.0% CAGR for 2025–2030.[3]
- The U.S. oncology market is projected to reach $189.6 billion by 2033 from $85.6 billion in 2024; the source covers oncology care and treatment spending in the United States.[6]
- The global community oncology-services market is projected to reach $79.95 billion by 2030 from $54.25 billion in 2025, a 7.9% CAGR for 2025–2030.[4]
05 Statistics
Strategy & Growth
Deal activity remains a channel for scale in oncology delivery, including Cardinal Health’s $1.12B acquisition of Integrated Oncology Network in December 2024.
M&A and consolidation in the oncology industry
- $2.49 billion bought a 70% controlling interest in Core Ventures in 2025, adding about 250 oncologists to The US Oncology Network.[7]
- 12 oncology practice-management transactions closed through June 2024, putting the U.S. sector on pace for a record year, according to Provident Healthcare Partners’ Q2 2024 update.[8]
- More than 100 providers at 50 sites in 10 states were consolidated when Cardinal Health acquired Integrated Oncology Network for $1.12 billion in December 2024.[7]
06 Statistics
Operating Benchmarks
Patient enrollment and reporting volume are tracked at scale, including 489,639 newly registered patients reported by 66 NCI-designated centers in the latest reporting year.
Operating metrics used in the oncology industry
- 47,052 patients were enrolled by 12 oncology practices and health systems in the first 15 months of the U.S. OncoPRO initiative; 52% completed at least one patient-reported-outcome survey.[9]
- 489,639 newly registered patients were reported by 66 U.S. NCI-designated clinical and comprehensive cancer centers in the latest reporting year, with 42 disease sites tracked.[10]
- $110 per beneficiary per month, or $140 for a dually eligible beneficiary, is the Enhancing Oncology Model monthly enhanced oncology-services payment effective January 1, 2025, for six-month systemic-chemotherapy episodes.[11]
07 Statistics
Delivery & Operations
Capacity and access constraints are explicit, including 68.5% of U.S. counties lacking a radiation-oncology practice site in 2025.
Delivery capacity and installed base in the oncology industry
- 427 U.S. counties experienced a net loss of radiation-oncology practice sites between 2018 and 2025.[12]
- 5,100 radiation oncologists were estimated to be practicing in the United States in 2024, including Veterans Affairs and pediatric-only radiation oncologists.[13]
- 68.5% of U.S. counties lacked a radiation-oncology practice site in 2025, representing 50.8 million residents without a local site.[12]
- Most U.S. cancer-center infusion services surveyed in late 2024 to early 2025 operated with 10–30 infusion chairs.[14]
08 Statistics
People & Workforce
Workforce supply remains a measurable constraint: 47% of surveyed U.S. cancer programs reported an oncologist vacancy in a 2025 Advisory Board survey.
Employment and hiring in the oncology industry
- 14,547 hematology and medical oncologists billed Medicare in the United States in 2024, equal to 14.9 oncologists per 100,000 adults aged 55 and older.[7]
- 47% of surveyed U.S. cancer programs reported an oncologist vacancy in a 2025 Advisory Board survey conducted among more than 100 oncology leaders.[15]
- 37% of U.S. hematology and medical oncologists were women in 2024, up from 30% in 2014; the count was 5,384 women oncologists.[7]
Skills and certification in the oncology industry
- 8 oncology nursing credential programs were offered by the Oncology Nursing Certification Corporation in the United States in 2024.[16]
- More than 41,000 nurses held an Oncology Nursing Certification Corporation credential in the United States in 2024; ONCC offered eight oncology nursing credential programs.[16]
- 5 Oncology Nursing Certification Corporation examinations were accredited by the National Commission for Certifying Agencies as of 2026, covering oncology nursing and related specialties.[17]
09 Statistics
Pricing
Episode-pricing adjustments show how oncology reimbursement is modeled, including a 2% quality-performance withhold in the U.S. Medicare Radiation Oncology Model.
Fees and price levels in the oncology industry
- 2% is the quality-performance withhold applied to the professional-component payment in the U.S. Medicare Radiation Oncology Model, under CMS episode-pricing rules currently governing participating radiation-oncology providers.[11]
- 3.5% is the Medicare Radiation Oncology Model professional-component discount factor for U.S. participants under the CMS model design, effective for model episode pricing; the model also applies case-mix and geographic adjustments.[11]
- 4.5% is the Medicare Radiation Oncology Model technical-component discount factor for U.S. participants under the CMS model design, effective for model episode pricing; the model covers equipment, supplies, personnel and related technical services.[11]
10 Statistics
Finance
Operational cost intensity is quantified in practice-level inputs, including $109.62 per hour of direct patient care as total direct expense in 2024.
Cost structure in the oncology industry
- $13.98 per hour of direct patient care was the supplies expense for U.S. hematology/oncology practices in the 2024 Physician Practice Information Survey.[18]
- $109.62 per hour of direct patient care was total direct expense for U.S. hematology/oncology practices in the 2024 Physician Practice Information Survey.[18]
- $92.73 per hour of direct patient care was the clinical expense for U.S. hematology/oncology practices in the 2024 Physician Practice Information Survey.[18]
Ownership and investment in the oncology industry
- 10% of U.S. medical oncologists and 15% of U.S. radiation oncologists practiced in private-equity-owned clinics by 2022, according to a study of oncology practice ownership.[19]
- About one-quarter of more than 2,400 U.S. physician-practice acquisitions by private-equity firms from 2013 through 2024 involved oncology practices.[20]
- 54% of U.S. oncology practices reported hospital or health-system ownership, up from 20%, in a survey covering 75% of office-based physicians.[7]
11 Statistics
Risk & Compliance
HIPAA breach reporting timelines are fixed to calendar deadlines, while incidents can affect large cohorts, including 175,195 individuals in a February 15, 2024 incident.
Client data and confidentiality in the oncology industry
- 60 days after the calendar year ends is the reporting deadline for U.S. HIPAA breaches affecting fewer than 500 people, under HHS breach-reporting guidance.[21]
- 60 calendar days is the maximum period for U.S. HIPAA covered entities to notify HHS and affected individuals after discovering a breach affecting 500 or more people, under the HIPAA Breach Notification Rule.[21]
- 175,195 individuals were potentially affected by a February 15, 2024 unauthorized-access incident reported by South Texas Oncology and Hematology, PLLC.[22]
12 Statistics
Sustainability
Telemedicine and decentralization are tied to lower carbon outcomes, including an 81.3% reduction in greenhouse-gas emissions per oncology visit-day in 2020.
Energy, emissions and disclosure in the oncology industry
- 489 kilograms of CO2e were emitted per external-beam-radiotherapy treatment and 27 kilograms per delivered fraction in a French single-center assessment.[23]
- 75.3 million kilograms of CO2e could be avoided annually in the United States under a counterfactual model that maximally decentralized oncology care using telemedicine and local care.[24]
- 185 to 2,066 kilograms of CO2e was the estimated carbon footprint of a typical external-beam-radiotherapy treatment in France, varying by treatment and fractionation schedule.[23]
- 81.3% lower greenhouse-gas emissions per oncology visit-day, equal to a 36.4-kilogram CO2e reduction, occurred under a telemedicine-preferred model versus in-person-preferred care in 2020 in a U.S. cancer-care cohort.[24]
Key questions about the Oncology Industry
How large is the global oncology drugs market in 2026?
What is the expected growth rate for the oncology drugs market from 2026 to 2033?
Which companies lead the oncology industry?
How is AI adoption changing in oncology practice in 2026?
What does the oncology market structure look like by drug class and distribution of revenue?
What regulatory and clinical development activity was reported for oncology in 2025?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Thomas Lindqvist. (2026, February 13). Oncology Industry Statistics. Gitnux. https://gitnux.org/oncology-industry-statistics
Thomas Lindqvist. "Oncology Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/oncology-industry-statistics.
Thomas Lindqvist. 2026. "Oncology Industry Statistics." Gitnux. https://gitnux.org/oncology-industry-statistics.
Sources & references
39 sources cited across this report
jnj.com
- ascoai.org
grandviewresearch.com
thebusinessresearchcompany.com
chartis.com
stout.com
ascopubs.org
providenthp.com
asco.org
cancercenters.cancer.gov
cms.gov
astro.org
redjournal.org
iqueue.leantaas.com
advisory.com
oncc.org
stg-www.oncc.org
ama-assn.org
academic.oup.com
pharmacy.rutgers.edu
hhs.gov
mass.gov
pmc.ncbi.nlm.nih.gov
jamanetwork.com
cancer.gov
gco.iarc.who.int
who.int
fda.gov
iqvia.com
nature.com
lilly.com
roche.com
astrazeneca.com
amgen.com
novartis.com
merck.com
astellas.com
annualreview.pfizer.com
takeda.com
